Serostim®

DRUG2 trials

Sponsors

EMD Serono

Conditions

Human Immunodeficiency Virus InfectionsHuman Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

Phase 2

Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

CompletedNCT00294164

EMD SeronoHuman Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections

Start: 2001-03-31End: 2002-05-31Updated: 2014-03-26

An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome

CompletedNCT00294918

EMD SeronoHuman Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections

Start: 2001-09-30End: 2003-02-28Updated: 2014-03-26